There are currently 163 active clinical trials seeking participants for Acute Myeloid Leukemia research studies. The states with the highest number of trials for Autism participants are California, New York, Texas and Illinois.
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
NCT06068868
Recruiting
Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children, but most cases occur in adults. This study is to evaluate how safe ABBV-787 is and how it moves within the body in adult participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). Adverse events and maximum tolerated dose (MTD) of ABBV-787 will be assessed. ABBV-787 is an investigational drug being developed for the treatment of AML. Participants will receive ABBV-787 in esca... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: UC Davis Medical Center /ID# 252723, Sacramento, California +13 locations
Conditions: Acute Myeloid Leukemia
Register for Updates
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
NCT03246906
Recruiting
This randomized phase II trial includes a blood stem cell transplant from an unrelated donor to treat blood cancer. The treatment also includes chemotherapy drugs, but in lower doses than conventional (standard) stem cell transplants. The researchers will compare two different drug combinations used to reduce the risk of a common but serious complication called "graft versus host disease" (GVHD) following the transplant. Two drugs, cyclosporine (CSP) and sirolimus (SIR), will be combined with ei... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Hematologic and Lymphocytic Disorder, Blastic Plasmacytoid Dendritic Cell Neoplasm
Register for Updates
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
NCT04083170
Recruiting
This phase II trial studies the side effects of a cord blood transplant using dilanubicel and to see how well it works in treating patients with human immunodeficiency virus (HIV) positive hematologic (blood) cancers. After a cord blood transplant, the immune cells, including white blood cells, can take a while to recover, putting the patient at increased risk of infection. Dilanubicel consists of blood stem cells that help to produce mature blood cells, including immune cells. Drugs used in che... Read More
Gender:
All
Ages:
Between 6 months and 65 years
Trial Updated:
04/18/2024
Locations: University of California San Francisco, San Francisco, California +5 locations
Conditions: Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Refractory Anemia, HIV Infection
Register for Updates
A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
NCT05360160
Recruiting
Part 1b of this clinical research study is to find the highest tolerable dose of SNDX-5613 that can be given in combination with ASTX727 (a combination of the drugs decitabine/cedazuridine) and venetoclax for patients with acute myeloid leukemia (AML) or those with a mixed phenotype acute leukemia with a myeloid phenotype (MPAL). Part 2 of this study is to learn if the dose of study drugs found in Part 1b can help to control AML/MPAL
Gender:
All
Ages:
12 years and above
Trial Updated:
04/18/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia
Register for Updates
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
NCT05748197
Recruiting
The purpose of this study is to test the safety of ADCLEC.syn1 CAR T cells in people with relapsed or refractory AML. The researchers will try to find the highest dose of ADCLEC.syn1 CAR T cells that causes few or mild side effects in participants. Once the researchers find this dose, it will test it in a new group of participants to see if it is effective in treating their relapsed/refractory AML.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Acute Myeloid Leukemia
Register for Updates
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
NCT04128501
Recruiting
This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and azacitidine after a stem c... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/18/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia
Register for Updates
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
NCT05457556
Recruiting
This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical [haplo]) versus matched unrelated donors (MUD) in treating children, adolescents, and young adults with acute leukemia or myelodysplastic syndrome (MDS). HCT is considered standard of care treatment for patients with high-risk acute leukemia and MDS. In HCT, patients are given very high doses of chemotherapy and/or radiation therapy, which is intended to kill cancer cells... Read More
Gender:
All
Ages:
Between 6 months and 21 years
Trial Updated:
04/18/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama +55 locations
Conditions: Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia
Register for Updates
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML
NCT05735184
Recruiting
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: USC University of Southern California / Norris Comprehensive Cancer Center, Los Angeles, California +26 locations
Conditions: Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leukemia, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma
Register for Updates
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
NCT05035706
Recruiting
This clinical trial assesses how the immune system responds to leukemia tumors after low dose radiation delivered as part of standard of care. The information learned in this study may help them know if adding immunotherapy (a type of treatment that uses the immune system to fight cancer) can be helpful in future leukemia patients receiving radiation.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia, Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Register for Updates
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
NCT05986240
Recruiting
This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). [(FDA OOPD)]
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Montefiore Medical Center, Bronx, New York +1 locations
Conditions: AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06001788
Recruiting
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut +4 locations
Conditions: AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
Register for Updates
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
NCT03661307
Recruiting
This phase I/II trial studies how well quizartinib, decitabine, and venetoclax work in treating participants with acute myeloid leukemia or high risk myelodysplastic syndrome that is untreated or has come back (relapsed). Quizartinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as decitabine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from d... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia
Register for Updates